Replies to post #139870 on Biotech Values

[mcbio]

Results from the CO-PILOT study also bode well for VRTX' oral combo (Incivek + VX-222 +Riba) although if memory serves SVR4 there were nowhere near those from CO-PILOT.

In particular if SVR rates are lower for the VRTX combo relative to other HCV DAA combos, I just don't see how that combo will successfully compete down the road against the other combos that contain all QD components.